Hope and the Huntington Disease Pipeline
Episode 34, Apr 23, 2021, 10:00 AM
Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Daniel Claassen, MD, MS, director, Huntington’s Disease Clinic, and division chief, Behavioral and Cognitive Neurology, Vanderbilt University Medical Center. He discussed the recent news of trial program terminations from Roche and Wave Life Science and the hope that remains in the Huntington disease pipeline despite these setbacks.
In this episode, we spoke with Daniel Claassen, MD, MS, director, Huntington’s Disease Clinic, and division chief, Behavioral and Cognitive Neurology, Vanderbilt University Medical Center. He discussed the recent news of trial program terminations from Roche and Wave Life Science and the hope that remains in the Huntington disease pipeline despite these setbacks.
Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.